Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer.

ABSTRACT: Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2+ breast tumors. However, despite its clinical benefit, resistance to the drug may arise. Here we have created cellular models of neratinib resistance to investigate the mechanisms underlying such resistance. Chronic neratinib exposure of BT474 human HER2+ breast cancer cells resulted in the selection of several clones resistant to the antiproliferative action of the drug. The clones were characterized biochemically and biologically using a variety of techniques. These clones retained HER2 levels similar to parental cells. Knockdown experiments showed that the neratinib-resistant clones retained oncogenic dependence on HER2. Moreover, the tyrosine phosphorylation status of BT474 and the resistant clo

SUBMITTER: Romero-Perez I 

PROVIDER: S-EPMC11297914 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature